Ricerca

We are happy to share with you the latest news  on the Generation HD 1 study from Roche.

 

In summary: the total number of participants will increase from 660 (already enrolled) to 801 and the study will be extended also to China.

 

This expansion will strengthen the clinical, scientific and statistical value of data relating to the two different dosages of drug being administered: one administration every eight weeks (2 months) versus one administration every 16 weeks (4 months), for an observation period of 25 months.

 

The last week of August we went to San Giovanni Rotondo, Puglia Region.

We wanted to meet the team and the patients involved in the Generation HD1 study, currently being held at Casa Sollievo della Sofferenza Hospital, Huntington and Rare Diseases Unit.

The scientific committee of the Foundation has considered worthy of the LIRH Huntington Disease Research Award 2018 Dr. Caterina Fusilli, first author of the article "Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis".